Pozen to file NSAID/PPI combo
This article was originally published in Pharmaceutical Approvals Monthly
Pozen will file the NDA for the NSAID/PPI combination product PN 400 in mid-2009, the firm announced May 13. With partner AstraZeneca, Pozen developed the fixed-dose combination of the NSAID naproxen with the PPI esomeprazole to treat the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing gastric ulcers (1"The Pink Sheet" DAILY, Aug. 2, 2006). Pozen's announcement suggests that FDA has resolved its concerns about the appropriateness of reduction in gastric ulcers as an endpoint for approval of a gastroprotective claim for NSAID/PPI combos (2"Pharmaceutical Approvals Monthly," December 2008, p. 34)
You may also be interested in...
FDA is considering changes to the approval process for NSAID and proton pump inhibitor combination products that may result in the agency prohibiting the use of endoscopic gastric ulcer reduction to support a gastroprotective marketing claim
AstraZeneca will oversee global manufacturing, marketing, sales and distribution for the arthritis pain compound.
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.